Clinical Trials | November 24, 2025
Contineum MS drug stumbles in mid-stage trial
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Winlevi is authorized in EU for the treatment of acne vulgaris
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The move is expected to be crucial during health crises
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Subscribe To Our Newsletter & Stay Updated
